4.7 Article

Microfluidic Encapsulation of Prickly Zinc-Doped Copper Oxide Nanoparticles with VD1142 Modified Spermine Acetalated Dextran for Efficient Cancer Therapy

Journal

ADVANCED HEALTHCARE MATERIALS
Volume 6, Issue 11, Pages -

Publisher

WILEY
DOI: 10.1002/adhm.201601406

Keywords

-

Funding

  1. Jane and Aatos Erkko Foundation [4704010, 4704482]
  2. Academy of Finland [266846, 252215, 281300]
  3. Research Council of Lithuania [SEN-04/2015]
  4. University of Helsinki Research Funds
  5. Biocentrum Helsinki
  6. European Research Council under the European Union's Seventh Framework Programme (FP) [310892]
  7. Academy of Finland (AKA) [266846, 266846] Funding Source: Academy of Finland (AKA)

Ask authors/readers for more resources

Structural features of nanoparticles have recently been explored for different types of applications. To explore specific particles as nanomedicine and physically destroy cancer is interesting, which might avoid many obstacles in cancer treatment, for example, drug resistance. However, one key element and technical challenge of those systems is to selectively target them to cancer cells. As a proof-of-concept, Prickly zinc-doped copper oxide (Zn-CuO) nanoparticles (Prickly NPs) have been synthesized, and subsequently encapsulated in a pH-responsive polymer; and the surface has been modified with a novel synthesized ligand, 3-(cyclooctylamino)2,5,6- trifluoro-4-[(2-hydroxyethyl)-sulfonyl] benzenesulfonamide (VD1142). The Prickly NPs exhibit very effective cancer cell antiproliferative capability. Moreover, the polymer encapsulation shields the Prickly NPs from unspecific nanopiercing and, most importantly, VD1142 endows the engineered NPs to specifically target to the carbonic anhydrase IX, a transmembrane protein overexpressed in a wide variety of cancer tumors. Intracellularly, the Prickly NPs disintegrate into small pieces that upon endosomal escape cause severe damage to the endoplasmic reticulum and mitochondria of the cells. The engineered Prickly NP is promising in efficient and targeted cancer treatment and it opens new avenue in nanomedication.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available